24C.F C-RAD AB B
- Market cap
- EUR 66.8M
- P/E
- 17.0x
- P/B
- 1.87x
- ROE
- 16.4%
- Dividend yield
- 0.45%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 24C.F undervalued?
Graham number24C.F trades 18.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
C-RAD AB B fundamental analysis
No fundamental analysis for C-RAD AB B yet.
C-RAD AB B stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About C-RAD AB B
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+…
Full company profileC-RAD AB B financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
C-RAD AB B annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 301M | 425M | 469M | 442M | 416M |
| Gross Profit | 205M | 287M | 323M | 316M | 310M |
| Operating Income | 21.8M | 49.8M | 70.4M | 60.6M | 65.9M |
| EBITDA | 32.0M | 53.2M | 89.9M | 27.1M | 80.0M |
| Net Income | 7.48M | 35.5M | 56.4M | 10.5M | 61.2M |
| EPS | 0.22 | 1.05 | 1.68 | 0.31 | 1.86 |
| Balance Sheet | |||||
| Total Assets | 339M | 406M | 489M | 501M | 511M |
| Total Liabilities | 96.6M | 134M | 164M | 154M | 137M |
| Shareholders' Equity | 243M | 271M | 325M | 347M | 374M |
| Cash & Short-term Investments | 122M | 129M | 151M | 171M | 144M |
| Cash Flow | |||||
| Operating Cash Flow | 9.69M | 33.4M | 29.9M | 71.1M | -10.3M |
| Capital Expenditure | 11.2M | 16.9M | 6.67M | 20.8M | 0.00 |
| Free Cash Flow | -1.53M | 16.5M | 29.9M | 50.3M | -10.3M |
| Ratios | |||||
| ROE | 3.1% | 13.1% | 17.4% | 3.0% | 16.4% |
| ROA | 2.2% | 8.8% | 11.5% | 2.1% | 12.0% |
| Net Profit Margin | 2.5% | 8.4% | 12.0% | 2.4% | 14.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
C-RAD AB B dividends
- Dividend yield
- 0.45%
- Forward dividend
- 0.01 EUR
- Payout ratio
- -
- Ex-dividend date
- May 8, 2026
Who owns C-RAD AB B
- Insiders 46.23%
- Institutions 28.32%
- Public & others 25.45%
- Shares outstanding 31.9M
- Free float 561K
C-RAD AB B company profile
- Company name
- C-RAD AB B
- Ticker
- 24C.F
- ISIN
- SE0002016352
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 98
- Fiscal year end
- December
- Address
- Sjukhusvägen 12K, Uppsala, Sweden, 753 09
- Phone
- 46 18 666 930
- Website
- c-rad.com
About C-RAD AB B
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports proton therapy from simulation to treatment; Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gating; and Sentinel 4DCT, a laser-based optical surface scanning system. It also provides Catalyst, a 4D surface guided radiation therapy (SGRT) solution; Catalyst HD, a SGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; and visual coaching solutions used for prospective and retrospective radiotherapy. In addition, the company offers cAutoVerify, an automation solution for the imaging suite and treatment room, automating patient identity validation, and accessory tracking. Further, it provides HIT1, HIT3, and HIT5 patient positioning laser, as well as laser positioning products and solutions. Additionally, the company offers support and training services; and service contracts. C-Rad AB (publ) was incorporated in 2004 and is headquartered in Uppsala, Sweden.
C-RAD AB B management
10- Ms. Linda FrölénChief Financial Officer · born 1977
- Mr. Johan DanielssonDeputy CEO & COO · born 1976
- Mr. Tomas BlomquistChief Executive Officer · born 1970
- Ms. Eeva-Liisa KarjalainenChief Product & Technology Officer
- Ms. Lina JohanssonChief Human Resources Officer · born 1985
- Mr. Xiaodong WangPresident of Sales Greater APAC · born 1979
- Mr. Ivan AstralagaPresident of Sales Americas · born 1968
- Mr. Vincent TallierPresident Sales EMEA & Head of Global Marketing · born 1979
- Mr. Andreas JuhlinChief Commercial Officer · born 1974
- Basak KarakusExecutive for Global Digital Marketing